Although our study did not find any correlation between FAK expression or activity and survival, suggesting that they are not prognostic biomarkers in lung cancer patients, the present workflow may be used to further assess FAK expression and activity as predictive biomarkers of response (theranostic biomarker) to FAK TKI in future clinical trials. Here, PTK2 is linked to lung carcinoma.